Katherine Stueland - Dec 16, 2023 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
Chief Executive Officer, Director
Signature
/s/ Devin Schaffer, Attorney-in-Fact
Stock symbol
WGS
Transactions as of
Dec 16, 2023
Transactions value $
-$25,338
Form type
4
Date filed
12/19/2023, 09:26 PM
Previous filing
Dec 12, 2023
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Options Exercise $0 +18.8K +41.15% $0.00 64.3K Dec 16, 2023 Direct F1
transaction WGS Class A Common Stock Sale -$25.3K -11.7K -18.25% $2.16 52.6K Dec 18, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Restricted Stock Unit Options Exercise $0 -18.8K -7.14% $0.00 244K Dec 16, 2023 Class A Common Stock 18.8K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.